LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 147

Search options

  1. Article: Arterial blood gases made easy.

    Burns, Graham P

    Clinical medicine (London, England)

    2014  Volume 14, Issue 1, Page(s) 66–68

    MeSH term(s) Bicarbonates/blood ; Blood Gas Analysis ; Carbon Dioxide/blood ; Humans ; Hydrogen-Ion Concentration ; Metabolism ; Oxygen/blood ; Partial Pressure ; Respiratory Physiological Phenomena
    Chemical Substances Bicarbonates ; Carbon Dioxide (142M471B3J) ; Oxygen (S88TT14065)
    Language English
    Publishing date 2014-02-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 2048646-7
    ISSN 1473-4893 ; 1470-2118
    ISSN (online) 1473-4893
    ISSN 1470-2118
    DOI 10.7861/clinmedicine.14-1-66
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial.

    Chaganti, Sridhar / Maycock, Shanna / McIlroy, Graham / Jackson, Aimee E / Bishop, Rebecca / Johnson, Sarah / Kanfer, Edward / Kassam, Shireen / Cwynarski, Kate / Wrench, David J / Arumainathan, Arvind / Fox, Christopher P / Johnson, Rod J / McKay, Pamela / Paneesha, Shankara / Rowntree, Clare / Balotis, Constantine / Collins, Graham P / Davies, Andrew J /
    Wright, Josh / Burns, Sarah / Laurence, Arian Dominic John / Wheatley, Keith / Menne, Tobias

    Blood

    2024  

    Abstract: Post-transplant lymphoproliferative disorder (PTLD) is a rare complication of solid organ transplantation, and cytotoxic chemotherapy is associated with treatment-related morbidity and mortality. Current treatment takes a sequential, risk-stratified ... ...

    Abstract Post-transplant lymphoproliferative disorder (PTLD) is a rare complication of solid organ transplantation, and cytotoxic chemotherapy is associated with treatment-related morbidity and mortality. Current treatment takes a sequential, risk-stratified approach, patients with low-risk disease following initial immunotherapy can avoid escalation to immunochemotherapy. TIDaL is a prospective, single-arm phase 2 trial investigating the activity and tolerability of ibrutinib combined with risk-stratified therapy for first-line treatment of PTLD. Eligible patients were adults with newly-diagnosed CD20-positive B-cell PTLD after solid organ transplant and performance status 0 to 2. Initial treatment comprised 49 days of ibrutinib 560mg once daily, with 4 doses of weekly rituximab. Treatment response on interim scan and baseline international prognostic index were used to allocate patients to either a low-risk arm (who continued ibrutinib, alongside 4 further doses of 3-weekly rituximab) or high-risk (escalation to R-CHOP immunochemotherapy, ibrutinib continuing in patients aged <65 years). The primary outcome was complete response on interim scan, achieved by 11/38 patients (29%, 95% confidence interval (CI) 15% - 46%). This did not reach the pre-specified threshold for clinically significant activity. Secondary outcomes included allocation to the low-risk arm (41% of patients), 2-year progression-free survival (58%, 95% CI 44% - 76%), and 2-year overall survival (76%, 95% CI 63% - 91%). Adverse events were mostly haematological, gastrointestinal and infective. Whilst TIDaL does not support adding ibrutinib into first-line treatment of PTLD, increasing the proportion of patients who can be treated without cytotoxic chemotherapy remains an important aim of future research. This trial was registered as ISRCTN32667607.
    Language English
    Publishing date 2024-04-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2024023847
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The British HIV Association national clinical audit 2021: Management of HIV and hepatitis C coinfection.

    Raya, Reynie P / Curtis, Hilary / Kulasegaram, Ranjababu / Cooke, Graham S / Burns, Fiona / Chadwick, David / Sabin, Caroline A

    HIV medicine

    2022  Volume 24, Issue 4, Page(s) 471–479

    Abstract: Objectives: We aimed to describe clinical policies for the management of people with HIV/hepatitis C virus (HCV) coinfection and to audit routine monitoring and assessment of people with HIV/HCV coinfection attending UK HIV care.: Methods: This was a ...

    Abstract Objectives: We aimed to describe clinical policies for the management of people with HIV/hepatitis C virus (HCV) coinfection and to audit routine monitoring and assessment of people with HIV/HCV coinfection attending UK HIV care.
    Methods: This was a clinic survey and retrospective case-note review. HIV clinics in the UK participated in the audit from May to July 2021 by completing an online questionnaire regarding their clinic's policies for the management of people with HIV/HCV coinfection, and by contributing to a case-note review of people living with HIV with detectable HCV RNA who were under the care of their service.
    Results: Ninety-five clinics participated in the clinic survey; of these, 15 (15.8%) were regional specialist centres, 19 (20.0%) were HIV services with their own coinfection clinics, 40 (42.1%) were HIV services that referred coinfected individuals to a local hepatology service and 20 (21.1%) were HIV services that referred to a regional specialist centre. Eighty-one clinics provided full caseload estimates; of the approximately 3951 people with a history of HIV/HCV coinfection accessing their clinics, only 4.9% were believed to have detectable HCV RNA, 3.15% of whom were already receiving or approved for direct-acting antiviral (DAA) treatment. In total, 29 (30.5%) of the clinics reported an impact of COVID-19 on coinfection care, including delays or reductions in the frequency of services, monitoring, treatment initiation and appointments, and changes to the way that treatment was dispensed. Case-note reviews were provided for 283 people with detectable HCV RNA from 74 clinics (median age 42 years, 74.6% male, 56.2% HCV genotype 1, 22.3% HCV genotype 3). Overall, 56% had not received treatment for HCV, primarily due to lack of engagement in care (54.7%) and/or being uncontactable (16.4%).
    Conclusions: Our findings show that the small number of people with HIV with detectable HCV RNA in the UK should mean that it is possible to achieve HCV micro-elimination. However, more work is needed to improve engagement in care for those who are untreated for HCV.
    MeSH term(s) Humans ; Male ; Adult ; Female ; Hepacivirus/genetics ; Antiviral Agents/therapeutic use ; Retrospective Studies ; Coinfection/drug therapy ; Hepatitis C, Chronic/drug therapy ; HIV Infections/complications ; HIV Infections/drug therapy ; COVID-19 ; Hepatitis C/complications ; Hepatitis C/drug therapy
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2022-09-29
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2001932-4
    ISSN 1468-1293 ; 1464-2662
    ISSN (online) 1468-1293
    ISSN 1464-2662
    DOI 10.1111/hiv.13417
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Geographically targeted chronic infection screening: lessons from a hepatitis B pilot study in the UK.

    O'Ferrall, Angus M / MacElhinney-West, Alison / Bell, Mark S / Haslam, Michael P / Walker, Gemma / Norton, Donna / Burns, Sean A / Ferrier, Graham / Easom, Nicholas J W

    Transactions of the Royal Society of Tropical Medicine and Hygiene

    2022  Volume 117, Issue 6, Page(s) 403–406

    Abstract: Chronic hepatitis B (CHB) most commonly occurs following infection in early childhood. Prevalence varies markedly around the globe. Country of birth is therefore a strong predictor of CHB risk in adults. We used country of birth census data to predict ... ...

    Abstract Chronic hepatitis B (CHB) most commonly occurs following infection in early childhood. Prevalence varies markedly around the globe. Country of birth is therefore a strong predictor of CHB risk in adults. We used country of birth census data to predict CHB risk and carry out geographically targeted screening in East Yorkshire, UK. Despite engaging individuals born in high-prevalence countries with testing, we observed lower than expected prevalence in targeted highest-risk areas, which may indicate barriers to testing for people with undiagnosed CHB. Improved strategies for engagement with high-risk groups will be key for viral hepatitis elimination.
    MeSH term(s) Adult ; Humans ; Child, Preschool ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/epidemiology ; Pilot Projects ; Persistent Infection ; Hepatitis B ; Prevalence ; United Kingdom/epidemiology
    Language English
    Publishing date 2022-12-14
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 441375-1
    ISSN 1878-3503 ; 0035-9203
    ISSN (online) 1878-3503
    ISSN 0035-9203
    DOI 10.1093/trstmh/trac131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.

    Burns, Michael J / Ponting, David J / Foster, Robert S / Thornton, Benjamin P / Romero, Naiffer E / Smith, Graham F / Ashworth, Ian W / Teasdale, Andrew / Simon, Stephanie / Schlingemann, Joerg

    Journal of pharmaceutical sciences

    2023  Volume 112, Issue 12, Page(s) 3005–3011

    Abstract: N-Nitrosamines are a class of indirect acting mutagens, as their metabolic degradation leads to the formation of the DNA-alkylating diazonium ion. Following up on the in-silico identification of thousands of nitrosamines that can potentially be derived ... ...

    Abstract N-Nitrosamines are a class of indirect acting mutagens, as their metabolic degradation leads to the formation of the DNA-alkylating diazonium ion. Following up on the in-silico identification of thousands of nitrosamines that can potentially be derived from small molecule drugs and their known impurities described in a previous publication, we have now re-analyzed this dataset to apply EMA's Carcinogenic Potency Categorization Approach (CPCA) introduced with the 16th revision of their Q&A document for Marketing Authorization Holders. We find that the majority of potential nitrosamines from secondary amine precursors belongs to potency categories 4 and 5, corresponding to an acceptable daily intake of 1500 ng, whereas nitrosamines from tertiary amine precursors distribute more evenly among all categories, resulting in a substantial number of structures that are assigned the more challenging acceptable intakes of 18 ng/day and 100 ng/day for potency categories 1 and 2, respectively. However, the nitrosative dealkylation pathway for tertiary amine is generally far slower than the direct nitrosation on secondary amines, with a direct nitrosation mechanism suspected only for structures featuring electron-rich (hetero)aromatic substituents. This allows for greater focus towards those structures that require further review, and we demonstrate that their number is not substantial. In addition, we reflect on the nitrosamine risk posed by secondary amine API impurities and demonstrate that based on the ICH Q3A/B identification threshold unknown impurities may exist that could be transformed to relevant amounts of NA. We also demonstrate that the analytical sensitivity required for the quantification of high potency nitrosamines can be problematic especially for high dose APIs. In summary, the regulatory framework rolled out with the latest Q&A document represents a substantial improvement compared with the previous situation, but further refinement through interaction between manufacturers, regulators, not-for-profit and academic institutions will be required to ensure patient access to vital medicines without compromising safety.
    MeSH term(s) Humans ; Nitrosamines/chemistry ; Amines/chemistry ; Pharmaceutical Preparations
    Chemical Substances Nitrosamines ; Amines ; Pharmaceutical Preparations
    Language English
    Publishing date 2023-10-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3151-3
    ISSN 1520-6017 ; 0022-3549
    ISSN (online) 1520-6017
    ISSN 0022-3549
    DOI 10.1016/j.xphs.2023.10.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Influence of omega-3 polyunsaturated fatty acids from fish oil or meal on the structure of lipid microdomains in bovine luteal cells.

    Plewes, M R / Burns, P D / Graham, P E / Bruemmer, J E / Engle, T E

    Animal reproduction science

    2018  Volume 193, Page(s) 40–57

    Abstract: Biological membranes are composed of a lipid bilayer and proteins that form lipid microdomains. This study examined the effects of fish byproducts on lipid-protein interactions within lipid microdomains of bovine luteal cells. In Exp. 1 and 2, luteal ... ...

    Abstract Biological membranes are composed of a lipid bilayer and proteins that form lipid microdomains. This study examined the effects of fish byproducts on lipid-protein interactions within lipid microdomains of bovine luteal cells. In Exp. 1 and 2, luteal cells were prepared from corpora lutea (CL; n = 4 to 8) collected at an abattoir. Exp. 1 was conducted to optimize ultrasonication in a detergent-free protocol for isolation of lipid microdomains. A power setting of 10 to 20% was effective in isolating lipid microdomains from bulk lipid. In Exp. 2, cells were cultured in control medium or fish oil to determine influence of fish oil on distribution of lipid microdomain markers and prostaglandin F
    MeSH term(s) Animal Feed/analysis ; Animal Nutritional Physiological Phenomena/drug effects ; Animals ; Cattle ; Cells, Cultured ; Dietary Fats, Unsaturated/pharmacology ; Dietary Supplements ; Fatty Acids/metabolism ; Fatty Acids, Omega-3/pharmacology ; Female ; Fish Oils/chemistry ; Fish Oils/pharmacology ; Luteal Cells/drug effects ; Luteal Cells/metabolism ; Membrane Microdomains/drug effects ; Membrane Microdomains/metabolism ; Primary Cell Culture/veterinary
    Chemical Substances Dietary Fats, Unsaturated ; Fatty Acids ; Fatty Acids, Omega-3 ; Fish Oils
    Language English
    Publishing date 2018-03-31
    Publishing country Netherlands
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 429674-6
    ISSN 1873-2232 ; 0378-4320
    ISSN (online) 1873-2232
    ISSN 0378-4320
    DOI 10.1016/j.anireprosci.2018.03.036
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Effect of fish oil on lateral mobility of prostaglandin F

    Plewes, M R / Burns, P D / Graham, P E / Hyslop, R M / Barisas, B G

    Domestic animal endocrinology

    2017  Volume 58, Page(s) 39–52

    Abstract: Lipid microdomains are ordered regions on the plasma membrane of cells, rich in cholesterol and sphingolipids, ranging in size from 10 to 200 nm in diameter. These lipid-ordered domains may serve as platforms to facilitate colocalization of intracellular ...

    Abstract Lipid microdomains are ordered regions on the plasma membrane of cells, rich in cholesterol and sphingolipids, ranging in size from 10 to 200 nm in diameter. These lipid-ordered domains may serve as platforms to facilitate colocalization of intracellular signaling proteins during agonist-induced signal transduction. It is hypothesized that fish oil will disrupt the lipid microdomains, increasing spatial distribution of these lipid-ordered domains and lateral mobility of the prostaglandin (PG) F
    MeSH term(s) Animals ; Cattle ; Cell Membrane/chemistry ; Cell Membrane/drug effects ; Cell Membrane/metabolism ; Cells, Cultured ; Diffusion/drug effects ; Dinoprost/pharmacology ; Female ; Fish Oils/pharmacology ; Lipids/analysis ; Luteal Cells/ultrastructure ; Receptors, Prostaglandin/metabolism
    Chemical Substances Fish Oils ; Lipids ; Receptors, Prostaglandin ; prostaglandin F2alpha receptor ; Dinoprost (B7IN85G1HY)
    Language English
    Publishing date 2017-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 594468-5
    ISSN 1879-0054 ; 0739-7240
    ISSN (online) 1879-0054
    ISSN 0739-7240
    DOI 10.1016/j.domaniend.2016.08.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Book: Lecture notes

    Bourke, S. J / Burns, Graham P

    2015  

    Title variant Respiratory medicine
    Author's details Stephen J. Bourke, Graham P. Burns
    MeSH term(s) Respiratory Tract Diseases
    Language English
    Size 247 pages :, illustrations
    Edition Ninth edition.
    Document type Book
    ISBN 9781118652329 ; 1118652320
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

  9. Article ; Online: Effect of fish meal supplementation on spatial distribution of lipid microdomains and on the lateral mobility of membrane-bound prostaglandin F

    Plewes, M R / Burns, P D / Graham, P E / Bruemmer, J E / Engle, T E / Barisas, B G

    Domestic animal endocrinology

    2017  Volume 60, Page(s) 9–18

    Abstract: This study examined the effects of fish meal supplementation on spatial distribution of lipid microdomains and lateral mobility of prostaglandin ... ...

    Abstract This study examined the effects of fish meal supplementation on spatial distribution of lipid microdomains and lateral mobility of prostaglandin F
    MeSH term(s) Animal Feed/analysis ; Animal Nutritional Physiological Phenomena ; Animals ; Cattle ; Corpus Luteum/cytology ; Corpus Luteum/drug effects ; Diet/veterinary ; Dietary Supplements ; Female ; Fish Products ; Lipid Metabolism/drug effects ; Receptors, Prostaglandin/genetics ; Receptors, Prostaglandin/metabolism
    Chemical Substances Receptors, Prostaglandin ; prostaglandin F2alpha receptor
    Language English
    Publishing date 2017
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 594468-5
    ISSN 1879-0054 ; 0739-7240
    ISSN (online) 1879-0054
    ISSN 0739-7240
    DOI 10.1016/j.domaniend.2017.02.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Original publication: Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity.

    Panagiotou, Grigorios / Tee, Su Ann / Ihsan, Yasir / Athar, Waseem / Marchitelli, Gabriella / Kelly, Donna / Boot, Christopher S / Stock, Nadia / Macfarlane, James / Martineau, Adrian R / Burns, Graham P / Quinton, Richard

    Clinical endocrinology

    2020  Volume 93, Issue 5, Page(s) 629–630

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Humans ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2 ; Vitamin D/analogs & derivatives
    Chemical Substances Vitamin D (1406-16-2) ; 25-hydroxyvitamin D (A288AR3C9H)
    Keywords covid19
    Language English
    Publishing date 2020-09-10
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 121745-8
    ISSN 1365-2265 ; 0300-0664
    ISSN (online) 1365-2265
    ISSN 0300-0664
    DOI 10.1111/cen.14310
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top